



Balfour Capital Group Cardinal Health, Inc.

Cardinal Health is a global healthcare services and products company headquartered in Dublin, Ohio. It operates primarily through two segments:

- **Pharmaceutical and Specialty Solutions:** Distributes branded and generic pharmaceuticals, specialty drugs, and over-the-counter healthcare products.
- **Global Medical Products and Distribution (GMPD):** Manufactures and distributes medical and laboratory products, including surgical apparel and gloves.

The company serves over 100,000 locations, including hospitals, pharmacies, and clinics, focusing on improving cost-effectiveness and patient care .

1. Top 5 Competitors

Cardinal Health's primary competitors in the healthcare distribution and services sector include:

- McKesson Corporation
- Cencora Inc.
- Medline Industries
- Owens & Minor
- Henry Schein

2. Largest Institutional Shareholders

As of April 2025, institutional investors hold approximately 86.9% of Cardinal Health's shares . Notable institutional shareholders include:

- Principal Financial Group Inc.
- Teacher Retirement System of Texas

Additionally, Robert D. Walter, the company's founder, is the largest individual shareholder, owning 4.5 million shares, representing 1.89% of the company .

3. Management Team

Key members of Cardinal Health's executive leadership include:

- Jason M. Hollar – Chief Executive Officer
- Steve Mason – CEO, Medical Segment
- Jessica L. Mayer – Chief Legal and Compliance Officer
- Michelle Greene – Chief Information Officer
- Debbie Weitzman – CEO, Pharmaceutical Segment

The executive team is recognized for its diverse expertise and leadership within the healthcare industry.



Balfour Capital Group Cardinal Health, Inc.

4. Revenue

For fiscal year 2024, Cardinal Health reported revenues of \$226.8 billion, marking an 11% increase from the previous year. In the second quarter of fiscal year 2025, the company reported revenues of \$55.3 billion.

5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for Cardinal Health:

- UBS: Set a price target of \$170 on May 2, 2025.
- Zacks Investment Research: Assigned a Rank #2 (Buy) rating.
- TipRanks: Consensus rating of "Strong Buy" based on 10 Wall Street analysts.

6. Analyst Sentiment Summary

Analyst sentiment towards Cardinal Health is generally positive:

- Consensus Rating: "Moderate Buy" with an average rating score of 2.71, based on 10 buy ratings and 4 hold ratings.
- Average Target Price: \$159.79.
- Earnings Forecast: Earnings are projected to grow by 8.7% annually, with EPS expected to increase by 10.2% per year.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, there has been significant insider selling activity:

- Jason M. Hollar (CEO): Sold shares worth approximately \$7.97 million.
- Debbie Weitzman (CEO, Pharmaceutical Segment): Sold shares valued at about \$4.5 million.
- Jessica L. Mayer (Chief Legal and Compliance Officer): Sold shares totaling around \$6.46 million.
- Stephen M. Mason (CEO, Medical Segment): Sold shares worth approximately \$3.27 million.

In the last 3 months alone, corporate insiders have sold shares valued at \$432.9K.